Legend Biotech’s (LEGN) “Outperform” Rating Reaffirmed at Royal Bank of Canada
Royal Bank of Canada reissued their outperform rating on shares of Legend Biotech (NASDAQ:LEGN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $84.00 price target on the stock. Several other research analysts have also recently issued reports on LEGN. Guggenheim reiterated a “neutral” rating on shares of Legend […]
Royal Bank of Canada reissued their outperform rating on shares of Legend Biotech (NASDAQ:LEGN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $84.00 price target on the stock. Several other research analysts have also recently issued reports on LEGN. Guggenheim reiterated a “neutral” rating on shares of Legend […]